A novel therapeutic drug for selective treatment of castration-resistant prostate cancer with MTAP deficiency

Chemotherapy is currently the most effective approach for treatment of advanced cancer. However, chemotherapeutics do not differentiate between malignant and normal cells, and lead to serious side effects. Recent findings indicate that a substantial proportion of cancers, as distinct from normal tissue, are deficient in an enzyme called methylthioadenosine phosphorylase (MTAP). This provides a unique […]

Read More